Business Description
BioCryst Pharmaceuticals Inc
NAICS : 325411
SIC : 2833
ISIN : US09058V1035
Share Class Description:
MEX:BCRX: Ordinary SharesTotal Employee Number:
435Description
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.32 | |||||
Equity-to-Asset | -4.79 | |||||
Debt-to-Equity | -0.37 | |||||
Debt-to-EBITDA | -2.16 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -5.54 | |||||
Beneish M-Score | -9.63 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 40 | |||||
3-Year Book Growth Rate | 29.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 10.29 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 99.97 | |||||
9-Day RSI | 98.78 | |||||
14-Day RSI | 94.28 | |||||
3-1 Month Momentum % | -11.5 | |||||
6-1 Month Momentum % | -6.23 | |||||
12-1 Month Momentum % | -24.27 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.91 | |||||
Quick Ratio | 1.88 | |||||
Cash Ratio | 1.33 | |||||
Days Inventory | 104.75 | |||||
Days Sales Outstanding | 40.55 | |||||
Days Payable | 187.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.3 | |||||
Shareholder Yield % | 6.2 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 97.76 | |||||
Operating Margin % | -43.11 | |||||
Net Margin % | -51.71 | |||||
EBITDA Margin % | -42.67 | |||||
FCF Margin % | 35.13 | |||||
OCF Margin % | 35.43 | |||||
ROA % | -96.91 | |||||
ROIC % | -244.25 | |||||
3-Year ROIIC % | 289.37 | |||||
ROC (Joel Greenblatt) % | -1880.33 | |||||
ROCE % | -129.43 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 28.1 | |||||
PS Ratio | 2.52 | |||||
Price-to-Free-Cash-Flow | 6.93 | |||||
Price-to-Operating-Cash-Flow | 6.88 | |||||
EV-to-EBIT | -8 | |||||
EV-to-Forward-EBIT | 65.13 | |||||
EV-to-EBITDA | -8.01 | |||||
EV-to-Revenue | 3.42 | |||||
EV-to-Forward-Revenue | 4.54 | |||||
EV-to-FCF | 10.05 | |||||
Price-to-GF-Value | 0.79 | |||||
Price-to-Median-PS-Value | 0.21 | |||||
Earnings Yield (Greenblatt) % | -12.51 | |||||
FCF Yield % | 12.66 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BioCryst Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 16,178.7 | ||
| EPS (TTM) (MXN) | -31.227 | ||
| Beta | -1.052 | ||
| 3-Year Sharpe Ratio | -0.05 | ||
| 3-Year Sortino Ratio | -0.09 | ||
| Volatility % | 59.86 | ||
| 14-Day RSI | 94.28 | ||
| 14-Day ATR (MXN) | 2.345661 | ||
| 20-Day SMA (MXN) | 155.7275 | ||
| 12-1 Month Momentum % | -24.27 | ||
| 52-Week Range (MXN) | 118 - 197.5 | ||
| Shares Outstanding (Mil) | 254.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioCryst Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioCryst Pharmaceuticals Inc Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-03 08:30 | In 125 days | ||
| Third quarter earnings results for 2026 | 2026-11-03 | In 124 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-04 08:30 | In 34 days | ||
| Second quarter earnings results for 2026 | 2026-08-04 | In 33 days | ||
| General meeting for 2025 | 2026-06-11 10:00 | 149.57 (+0.00%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 15:45 | 149.57 (+0.00%) | ||
| Bank of America Health Care Conference | 2026-05-12 16:40 | 149.57 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-06 08:30 | 159.00 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 159.00 (+0.00%) | ||
| T.D. Cowen 46(th) Annual Health Care Conference | 2026-03-03 09:10 | 148.50 (-0.67%) |
Show
Entries
BioCryst Pharmaceuticals Inc Frequently Asked Questions
What is BioCryst Pharmaceuticals Inc(MEX:BCRX)'s stock price today?
The current price of MEX:BCRX is MXN175.00. The 52 week high of MEX:BCRX is MXN197.50 and 52 week low is MXN118.00.
When is next earnings date of BioCryst Pharmaceuticals Inc(MEX:BCRX)?
The next earnings date of BioCryst Pharmaceuticals Inc(MEX:BCRX) is 2026-08-04 Est..
Does BioCryst Pharmaceuticals Inc(MEX:BCRX) pay dividends? If so, how much?
BioCryst Pharmaceuticals Inc(MEX:BCRX) does not pay dividend.
Press Release
Articles on BioCryst Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers